A Phase II Study to Evaluate the Efficacy of IdeS (IgG Endopeptidase) to Desensitize Transplant Patients With a Positive Crossmatch Test

Trial Profile

A Phase II Study to Evaluate the Efficacy of IdeS (IgG Endopeptidase) to Desensitize Transplant Patients With a Positive Crossmatch Test

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs Imlifidase (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms Highdes
  • Sponsors Hansa Medical AB
  • Most Recent Events

    • 14 Feb 2018 Primary endpoint of IdeS ability to create a negative crossmatch test has been met, according to a Hansa Medical AB media release.
    • 14 Feb 2018 According to a Hansa Medical AB media release, results will be presented at the 138th Annual Meeting of the American Surgical Association (ASA) and final results, including six months follow up data from all 18 patients are expected mid/Q3 2018.
    • 04 Jan 2018 According to a Hansa Medical media release, final results are expected during the third quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top